CHICAGO, April 1 (Reuters) - The Sanofi-Aventis SA weight loss drug rimonabant failed to slow heart disease by a key measure in obese patients with fat around the middle, and it significantly increased the risk of anxiety and depression, U.S. researchers said on Tuesday.
